DBV Technologies Receives FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of Peanut Allergy in Children

  • DBV Technologies is the first company to announce Breakthrough Therapy Designation from FDA in food allergy
  • Breakthrough Designation granted following positive Phase IIb results emphasizing the need to provide a safe pharmaceutical treatment for patients suffering from life threatening food allergies

BAGNEUX, France, April 9, 2015 - DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Viaskin® Peanut for children.

To download the full version of the Press Release in English language, please click on the following link: